Skip to main content
. 2022 Dec 29;11(1):76. doi: 10.3390/vaccines11010076

Figure 3.

Figure 3

Mt10 vaccine induces nAbs against CVB4. Sera were collected from recipients of saline (top left), Mt10, (top right) and Mt10 + CVB4 (bottom) on days 14, 21, and 56. Two-fold serial dilutions from 1:40 up to 1:40,960 were made, and samples were incubated with CVB1, CVB3, or CVB4. The mixtures were later transferred to plates containing monolayers of LLC-MK2 cells for CVB1 or Vero cells for CVB3 and CVB4 and incubated for 4 days to calculate the percentage neutralization based on CPE. The top left panel indicates the nAb titers determined against CVB1, CVB3, and CVB4 in the saline group that served as a baseline. The top right panel indicates the nAbs determined in the Mt10 vaccine group against CVB1, CVB3, and CVB4 at three different time points, and the profiles were compared. The bottom panel indicates the nAb titers determined in the Mt10 vaccinated/CVB4 challenged group and the profiles were compared with those of Mt10 vaccine group at termination (day 56). Data from n = 3–8 samples are shown. Two-way ANOVA with Sidak’s post-test was used to compare significance of nAb titers. * p ≤ 0.05, *** p ≤ 0.001.